Hyperprolactinemia and Adrenal Steroidogenesis

Learn more about:
Related Clinical Trial
Administration of Kisspeptin to Subjects With Reproductive Disorders The Luveris In Vitro Fertilization Trial A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Pituitary Function and Spontaneous Intracranial Hypotension Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility Aripiprazole and Prolactin Study Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Characterization of Macroprolactinemia Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) Endometriosis Patients Undergoing Quinagolide Treatment Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire Hyperprolactinemia and Adrenal Steroidogenesis Administration of Kisspeptin in Patients With Hyperprolactinemia Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

Brief Title

Hyperprolactinemia and Adrenal Steroidogenesis

Official Title

Hyperprolactinemia and Adrenal Steroidogenesis: is There a Link?

Brief Summary

      The purpose of this study is to explore the effects of prolactin on adrenal steroid profiles
      in patients with hyperprolactinemia due to prolactinomas before and after initialisation of
      treatment.
    

Detailed Description

      Prolactin is known to influence many biological processes. One potential target is the
      adrenal gland, where prolactin may stimulate the production of adrenal steroid hormones.
      Conditions of increased prolactin production(hyperprolactinemia) could, therefore, increase
      concentrations of adrenal steroids. One of the potential implications would be false doping
      accusations of athletes engaging in elite sports.

      This interaction between prolactin and adrenal steroidogenesis, however, remains poorly
      understood, and the available research findings are conflicting.

      The investigators, therefore, seek to explore the relationship between prolactin and adrenal
      steroidogenesis by monitoring prolactin levels and blood and urinary steroid profiles of
      patients with hyperprolactinemia due to prolactinomas before and after treatment
      initialisation.
    


Study Type

Observational


Primary Outcome

Covariation of plasma prolactin and plasma dehydroepiandrosterone

Secondary Outcome

 Change in the plasma steroid profile

Condition

Hyperprolactinemia



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

17

Start Date

June 24, 2021

Completion Date

June 1, 2022

Primary Completion Date

May 1, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Aged 18 years or older

          -  Female and pre-menopausal

          -  Serum prolactin > 150 ng/ml

        Exclusion Criteria:

          -  Corticotropic and/or thyreotropic insufficiency

          -  Pregnancy, planned pregnancy or breastfeeding

          -  Physical or psychological condition likely to interfere with the normal conduct of the
             study and interpretation of the study results as judged by the investigator

          -  Incapacity to give informed consent
      

Gender

Female

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Lia Bally, MD PhD, +41 (0)31 632 36 77, [email protected]

Location Countries

Switzerland

Location Countries

Switzerland

Administrative Informations


NCT ID

NCT04146389

Organization ID

Prado


Responsible Party

Sponsor

Study Sponsor

University Hospital Inselspital, Berne


Study Sponsor

Lia Bally, MD PhD, Principal Investigator, Inselspital, Bern University Hospital, University of Bern


Verification Date

August 2021